Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

Market in consolidation phase, break above 24,600 crucial for trend shift: Gautam Shah

Published

on

Market in consolidation phase, break above 24,600 crucial for trend shift: Gautam Shah
The Indian equity market is entering a phase of sharp sectoral rotation, where leadership is narrowing and thematic investing is gaining importance. According to Gautam Shah from Goldilocks Global Research while the broader indices may remain capped in the near term, sectors like energy, PSU, metals, and select pockets of real estate and pharma are setting up for stronger upside trends.

Energy remains a structural story

Shah reiterated his long-standing bullish view on energy, calling it a structural theme with durable tailwinds.

“Energy is a structural play. There are a lot of fundamental tailwinds there. Valuations seem to be comfortable and the government is at play, helping many of the Indian companies to do much bigger things on a global scale. Given all of that and given the way the charts are, I do believe that energy is a structural play and we are looking at the index going back to the previous highs at least. That would be the first working target and then much bigger upside. So, the entire basket of power and energy stocks looks good to me. We have obviously been committed to it for a couple of months now and we are playing test cricket here. We are not looking at getting out very quickly. So, think big. There is another 15% to 20% upside on the index and you just stay committed. There will be dips from time to time because the rally has been large and every time that dip happens it might be a good idea to buy fresh.”

Advertisement

He added that investors can either accumulate baskets or focus on selective stock picking within the space.

Auto sector under pressure
On autos, Shah maintained a negative stance and expects meaningful underperformance ahead.
“We would be negative on auto, I think that has been the stance for a couple of months now. And with auto being a direct reflection of the economy and with the way the charts are placed, there is a greater possibility of the auto index actually losing about 10-12% from here and going back to the March lows. Now, if that were to happen, then there is a big problem because a lot of stocks will come off substantially.”
He added that both autos and FMCG could remain under pressure if largecaps fail to show leadership.
Nifty stuck in a tight range
On the broader index, Shah expects consolidation with a defined trading band and limited upside unless key resistance levels are breached.

“24,600 on multiple counts was and remains a very important resistance. And as you might have noticed in the last seven days, the market is just taking a breather. There seems to be a fierce battle between the bulls and the bears within a very tight range, 23,800 on the downside and 24,250 and 24,600 on the upside. Till the Nifty does not get past 24,600, I would be cautious, I would be conservative and there is a greater possibility of a breakdown below 23,800.”

He highlighted weak leadership from IT, banking, and Reliance Industries, which together form a large part of the index.

Banks and IT remain weak links
Shah expressed caution on banks, particularly private lenders, which he believes could weigh on the index.

Advertisement

“Look at what HDFC Bank has done in this entire April recovery and look at where it is today in comparison to the rest of the banking space. When you have HDFC and ICICI Bank undergoing such a phase of underperformance and not being able to rally for whatever reasons, questions about their growth, FII selling, the fact that they are all richly valued versus peers around the world, you can put out a lot of cases there. But it is out there that private banks are underperforming and if that is going to continue, Nifty will find it difficult to rally.”

He added that PSU banks remain mixed, with only one large name standing out.

Sector rotation into PSUs, metals and pharma
Shah believes the market is now entering a phase of rotational strength across previously underperforming sectors.

He remains bullish on PSU, metals, defence, capital goods, and real estate over a 6–12 month horizon. He also sees early signs of revival in chemicals, textiles, and pharma.

Advertisement

“Pharma is one space that we continue to like… a bigger breakout is coming after 18 months of consolidation and it will do exceedingly well.”

On metals, he remains strongly constructive with a long-term structural view:

“Our working target for the NSE Metals Index is about 14,000… The rest of this year will belong to metals.”

Real estate showing bottoming signs
Shah sees real estate as a high-conviction medium-term opportunity after a deep correction.

Advertisement

“We are going to see a large 25% rally on the index from current levels… So, it is an opportunity, but do not look at it short term. There will be volatility in the short term, but now they will start a sequence of higher tops and higher bottoms.”

Crude oil and macro risks
On crude oil, Shah flagged it as a key risk factor for India.

“Nymex crude is likely to remain elevated… eventually it can gradually go towards a 120-125 number. Now if that were to happen, it is definitely a big impact on the economy more medium-term.”

He also pointed to rupee weakness and global AI-driven disruption as additional headwinds for foreign inflows.

Advertisement

Final takeaway: be selective and concentrated
Summing up his strategy, Shah advised a focused approach rather than broad diversification.

“Be concentrated, be in companies that have less to do with foreign policy and be with companies that have relative better earnings visibility for the next three to five years. Anything and everything in this market will not work because you do not have the index tailwind in your favour.”

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Q1: 2026-05-05 Earnings Summary

EPS of $0.44 misses by $0.43

 | Revenue of $58.82M (10.28% Y/Y) misses by $3.58M

Rigel Pharmaceuticals, Inc. (RIGL) M&A Call May 12, 2026 8:00 AM EDT

Company Participants

Raymond Furey – Executive VP, Chief Compliance Officer, General Counsel & Corporate Secretary
Raul Rodriguez – President, CEO & Director
Lisa Rojkjaer – Executive VP & Chief Medical Officer
Erika Hamilton
David Santos – Executive VP & Chief Commercial Officer

Advertisement

Conference Call Participants

Joseph Pantginis – H.C. Wainwright & Co, LLC, Research Division
Kristen Kluska – Cantor Fitzgerald & Co., Research Division
Yigal Nochomovitz – Citigroup Inc., Research Division
Farzin Haque – Jefferies LLC, Research Division
Ashleigh Acker – Piper Sandler & Co., Research Division

Advertisement

Presentation

Operator

Greetings. Welcome to Rigel Pharmaceutical VEPPANU Licensing Agreement Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce our first speaker, Ray Furey, Rigel’s Executive Vice President, General Counsel and Corporate Secretary. Thank you, Mr. Furey. You may begin.

Advertisement

Raymond Furey
Executive VP, Chief Compliance Officer, General Counsel & Corporate Secretary

Welcome to our conference call to discuss Rigel’s in-licensing of VEPPANU or Vepdegestrant. The press release announcing the transaction was issued earlier this morning and can be viewed along with the slides for this presentation in the News and Events section of Investor Relations site on rigel.com.

As a reminder, during today’s call, we may make forward-looking statements regarding our plans and timing for the regulatory review of the transaction and development and commercialization of VEPPANU. In addition, as noted in the press release issued this morning and here in the presentation, this transaction is subject to customary closing conditions, including review under the Hart-Scott-Rodino Antitrust Improvements Act. The statements made today are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks are identified in the slides and in our most recent annual report on Form 10-K for the year ended December

Advertisement
Continue Reading

Business

Monex Group, Inc. 2026 Q4 – Results – Earnings Call Presentation (OTCMKTS:MNXBF) 2026-05-12

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

This article was written by

Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Continue Reading

Business

Tennessee Democrats stripped of House committee seats over redistricting protests

Published

on

Tennessee Democrats stripped of House committee seats over redistricting protests


Tennessee Democrats stripped of House committee seats over redistricting protests

Continue Reading

Business

Cal-Maine acquires frozen food business

Published

on

Cal-Maine acquires frozen food business

Van’s Foods is a manufacturer of frozen breakfast foods. 

Continue Reading

Business

Air India crisis deepens ahead of final Ahmedabad crash report

Published

on

Air India crisis deepens ahead of final Ahmedabad crash report

Air India faces a leadership vacuum and mounting financial losses as it struggles to recover from the crash.

Continue Reading

Business

Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Q1: 2026-05-06 Earnings Summary

EPS of -$0.85 misses by $1.33

 | Revenue of -$29.00K (-100.96% Y/Y) misses by $109.31M

Vir Biotechnology, Inc. (VIR) Bank of America Global Healthcare Conference 2026 May 12, 2026 7:20 PM EDT

Company Participants

Marianne De Backer – President, CEO & Director

Advertisement

Conference Call Participants

Alec Stranahan – BofA Securities, Research Division

Advertisement

Presentation

Alec Stranahan
BofA Securities, Research Division

Thanks for joining the session with Vir Biotechnology. My name is Alec Stranahan. I cover SMID-cap biotech at Bank of America, and I’m the covering analyst for Vir. And it’s my pleasure to introduce Marianne De Backer, Chief Executive Officer of Vir. Marianne, thanks for being here.

Advertisement

Marianne De Backer
President, CEO & Director

Yes, my pleasure. Thank you.

Advertisement

Question-and-Answer Session

Alec Stranahan
BofA Securities, Research Division

Looking forward to the discussion. I guess just jumping right into it, you’ve effectively built a 2-engine value story for Vir. You’ve got the near-term potential from HDV, which we can talk about and the longer-term oncology platform using the PRO-XTEN technology. I guess when you look at how the market is valuing the company today, where do you see the biggest opportunity for re-rating? Is it on HDV approval and launch? Is it on the VIR-5500 progress to registrational studies? Or is it maybe the broader platform as the TCE data matures?

Advertisement

Marianne De Backer
President, CEO & Director

Sure. Yes. Thank you. And thank you, Alec, for hosting us and Bank of America for hosting Vir Biotechnology. So we are very fortunate that at Vir Biotechnology, we have multiple pathways to value creation, as you point out. Obviously, our most advanced program is our delta program, already in registrational trial, initial data are going to read out starting fourth quarter of this year. So obviously, that’s an important route to value creation near term.

And then as you mentioned, we have a portfolio of 3 clinical assets, 3 clinical

Advertisement
Continue Reading

Business

Surviving When Predictive Models Break

Published

on

Surviving When Predictive Models Break

Yesterday’s chaotic nine-goal thriller between Paris Saint-Germain and Bayern Munich completely shattered every conservative forecasting model on the market.

By examining the massive collapse of predictive algorithms during that specific match, business leaders can learn brutal, necessary lessons about surviving sudden operational chaos.

Corporate executives love to boast about making “calculated, data-driven decisions,” totally ignoring the fact that most financial forecasts are incredibly fragile. You can hire the most expensive analysts, build a massive spreadsheet and present a flawless quarterly projection to the board, but the reality of business is inherently volatile. When a massive supply chain failure or a sudden regulatory change hits your sector, the historical data is basically useless. To truly understand how quickly a supposedly perfect model can disintegrate, corporate leaders need to look outside the boardroom and study the aggressive, heavily scrutinized world of sports analytics. Yesterday’s Champions League clash is the absolute perfect case study.

No sane predictive model anticipated a 5-4 result between two European heavyweights. Examining the pre-match analytics on platforms like ThePuntersPage provides a brilliant corporate baseline, showing exactly what the smartest algorithms in the world expected to happen. They expected a tight, heavily defensive chess match. Instead, they got absolute pandemonium. Watching how the market reacted to that unexpected chaos offers a masterclass in modern risk management for any scaling enterprise.

The Illusion of the Safe Corporate Bet

Before the referee even blew the whistle in Paris, the financial narrative was already fully settled. Every major syndicate and data analyst backed the under on total goals. The logic was completely sound: semi-finals are notoriously tense, both squads possess world-class defensive structures and the stakes were simply too high for either manager to risk playing an open, attacking style. It was the textbook definition of a “safe bet.”

Advertisement

This exact same mentality traps small and medium-sized enterprises every single day. Founders look at historical revenue charts and assume that because a specific product line or vendor relationship has been stable for three years, it will automatically remain stable for the fourth. They confuse historical consistency with future security. But relying entirely on past performance creates a massive operational blind spot. When you assume a market is safe, you stop aggressively monitoring the perimeter for threats. Just like the oddsmakers who totally failed to account for a sudden, aggressive tactical change in the first ten minutes of the match, companies that cling to their comfortable, safe bets are usually the first ones to get wiped out when the industry suddenly pivots.

Navigating the Black Swan Event

In financial terminology, a Black Swan is an unpredictable, incredibly rare event that carries severe consequences. Five goals being scored before the halftime whistle in a Champions League semi-final is the sporting equivalent of a Black Swan. It completely destroys the mathematical framework. When an event like this occurs, staring at your outdated dashboard and wondering why the numbers look wrong is a massive waste of time.

Corporate leaders constantly make the mistake of trusting the data even after the foundational reality has changed. According to a recent January 2026 financial analysison streamlining disconnected risk data, banks and massive corporations consistently fail to react to macroeconomic shocks because their internal reporting systems are too slow to process sudden, violent changes in the market. The algorithm cannot save you if the algorithm was built for a reality that no longer exists. When the match suddenly turns chaotic, or when a major competitor unexpectedly drops their pricing by forty percent, executives need to immediately abandon their rigid pre-planned models. Survival requires aggressive, real-time adaptation, totally disregarding the beautiful quarterly forecast that took three months to build.

Damage Control and the Art of Hedging

Perhaps the most valuable lesson from yesterday’s match is not how the models failed, but how Bayern Munich handled a catastrophic situation. Down 5-2 away from home, the German side was staring at total tournament elimination. An amateur manager would have panicked, thrown every single player forward and likely conceded three more goals on the counter-attack, completely bankrupting their chances for the second leg.

Advertisement

Instead, they executed perfect damage control. They tightened their structure, absorbed the pressure and managed to claw back two late goals to make it 5-4, entirely saving the aggregate tie. This is exactly how ruthless founders manage a terrible financial quarter. If a new product launch is failing miserably, you do not double down and burn the rest of your venture capital trying to force it to work. You cut your losses, hedge your remaining assets and mitigate the damage so the company lives to fight another day. Reviewing strategies on mastering risk management as a trader directly translates to this executive mindset. It is about understanding that sometimes, the goal is not to win the quarter. No, the goal is simply to stop the bleeding before the damage becomes terminal.

Building an Agile Operational Framework

Business culture heavily romanticizes the maverick CEO who stubbornly sticks to their initial vision regardless of what the market dictates. In 2026, operating with that level of stubborn pride is borderline negligence. The market does not care about your initial vision, and it certainly does not care about your perfectly formatted Excel spreadsheets.

To survive in an increasingly volatile commercial environment, small and medium enterprises must transition away from rigid, multi-year plans and build highly agile frameworks. You train your management team to view corporate metrics with the same ruthless, emotionally detached objectivity found in the live sports forecasting industry. You learn to read the room, identify the exact moment the historical data becomes useless and pivot your resources without hesitation. Stop treating your business forecasts like an absolute guarantee. Treat them like a pre-match probability that can, and inevitably will, get blown to pieces the second the reality of the market kicks in.

Advertisement
Continue Reading

Business

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Q1: 2026-05-05 Earnings Summary

EPS of -$1.54 misses by $0.08

 | Revenue of $136.00M (-2.36% Y/Y) misses by $22.41M

Ultragenyx Pharmaceutical Inc. (RARE) Bank of America Global Healthcare Conference 2026 May 12, 2026 5:20 PM EDT

Company Participants

Howard Horn – Executive VP of Corporate Strategy & CFO
Joshua Higa – Director of Investor Relations & Corporate Communications

Advertisement

Presentation

Unknown Analyst

I’m one of the biotech analysts here at BofA. Our next presenting company is Ultragenyx. And here with me are Howard Horn, Chief Financial Officer; and Josh Higa, Head of IR. Thank you for joining us, guys.

Advertisement

Question-and-Answer Session

Unknown Analyst

Advertisement

So I think there’s a lot going on at the company. I think most people are familiar with it, but maybe we can start with a quick overview of the company, kind of your commercial products, and you have a very busy second half of the year. So maybe you can highlight some of the key catalysts coming up.

Howard Horn
Executive VP of Corporate Strategy & CFO

Sure. Glad to, and thank you for having us. So Ultragenyx is a next-generation rare disease company on a pathway to profitability in 2027. We have 4 commercialized products, and we are estimating between $730 million and $760 million in revenue this year. We are hopeful to have 2 approvals and launches of 2 gene therapy programs this year. And the other data event people are waiting for is our Phase III data in Angelman that we talked about coming out in the second half of the year. So yes, it’s a very busy year.

Advertisement

Unknown Analyst

All right. Great. Maybe we can start with a quick question on the commercial side. So you recently reported earnings. I think there was a slight miss in the quarter, but you reaffirmed your guidance for the year. Maybe you can talk to us a little bit about 1Q dynamics and kind of what gives you

Advertisement
Continue Reading

Business

Preparing for the impact of GLP-1s

Published

on

Preparing for the impact of GLP-1s

Webinar speakers touched on how the drugs are affecting product formulation.

Continue Reading

Business

Sebi may relax norms for select agri commodity F&O contracts

Published

on

Sebi may relax norms for select agri commodity F&O contracts
Mumbai: The Securities and Exchange Board of India (Sebi) on Tuesday proposed to allow select agricultural commodity derivatives contracts to begin trading as cash settled instruments before transitioning to mandatory physical settlement.

The regulator said exchanges may be allowed on a pilot basis, to launch or revive delivery-based agricultural contracts that initially operate as financially settled products and later shift to compulsory physical settlement once predefined thresholds such as average daily traded volume, open interest levels, or a two-year period are met. “Liquidity formation in several agricultural contracts remains constrained, especially at the launch or relaunch stage. Low volumes and limited open interest can reduce market confidence, creating a feedback loop that further suppresses participation,” Sebi said in a discussion paper.

“Although accredited warehouses and assaying mechanisms have expanded, their utilisation in certain commodities remains limited.”

Sebi suggested that on a pilot basis, a couple of commodities could be considered under the proposed framework such as maize, groundnut and chilli.

Advertisement

In a separate development, Sebi has also proposed doubling the client-level open position limits across all categories of agri commodities.


Continue Reading

Trending

Copyright © 2025